Incyte Corporation
INCY
Rank in Stocks
#1034
Incyte Corporation is a biopharmaceutical firm engaged in the research,... Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Share Price
$112.84
Last synced: 2026-10-16
Market Cap
$22.87B
Change (1 day)
-0.38%
Change (1 year)
28.86%
Country
US
Trade Incyte Corporation (INCY)
Category
Healthcare
Operating Margin for Incyte Corporation (INCY)
Operating Margin as of October 2026 TTM: 31.57%
According to Incyte Corporation latest financial reports and stock price the company's current Operating Margin (TTM) is 31.57%. At the end of 2024 the company had an Operating Margin of 1.89%.
Operating Margin history for Incyte Corporation from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 31.57% | 7.16% |
| 2025 | 29.46% | 1,458.73% |
| 2024 | 1.89% | -88.74% |
| 2023 | 16.79% | -1.64% |
| 2022 | 17.07% | -13.00% |
| 2021 | 19.62% | -317.76% |
| 2020 | -9.01% | -148.39% |
| 2019 | 18.62% | 171.03% |
| 2018 | 6.87% | -143.29% |
| 2017 | -15.87% | -221.05% |
| 2016 | 13.11% | 95.09% |
| 2015 | 6.72% | -814.89% |
| 2014 | -0.94% | -79.30% |
| 2013 | -4.54% | -1,264.10% |
| 2012 | 0.39% | -100.26% |
| 2011 | -151.59% | -1,933.01% |
| 2010 | 8.27% | -100.55% |
| 2009 | -1,508.56% | -62.88% |
| 2008 | -4,064.53% | 1,541.44% |
| 2007 | -247.62% | -10.95% |
| 2006 | -278.06% | -78.35% |
| 2005 | -1,284.53% | 22.07% |
| 2004 | -1,052.26% | 231.91% |
| 2003 | -317.03% | 229.04% |
| 2002 | -96.35% | 226.50% |
| 2001 | -29.51% | -8.47% |
| 2000 | -32.24% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -98.78% |
US
|
|
| -149.01% | -104.72% |
US
|
|
| 25.57% | -99.19% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.09% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.